2011
Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management
Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 2496-2506. PMID: 22028406, PMCID: PMC3237732, DOI: 10.1158/1055-9965.epi-11-0635.Peer-Reviewed Original ResearchConceptsHuman epididymis protein 4Epithelial ovarian cancerSerum human epididymis protein 4Independent prognostic factorOvarian Malignancy AlgorithmPrognostic factorsMalignancy AlgorithmProgression-free survivalLymph node involvementOvarian cancer managementPreoperative serum samplesProtein 4Ovarian benign cystsElevated CA125Node involvementPositive cytologyPostmenopausal womenPremenopausal womenMultivariable analysisMulticenter studyPrognostic valueAdvanced ageOvarian cancerBenign cystsObstetricians stage
2008
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer
Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2008, 200: 75.e1-75.e10. PMID: 18976739, DOI: 10.1016/j.ajog.2008.08.014.Peer-Reviewed Original ResearchConceptsPeptide-specific cytotoxic T lymphocytesCytotoxic T lymphocytesHuman leukocyte antigenLeukocyte antigenOvarian cancerT lymphocytesHuman cytotoxic T-lymphocyte responsesCytotoxic T-lymphocyte precursor frequenciesNatural killer-sensitive targetsPeptide-loaded target cellsType 1 cytokine profileCytotoxic T lymphocyte responsesT lymphocyte precursor frequenciesPotential immunogenic peptidesAdvanced ovarian cancerClass I antibodiesIntracellular cytokine expressionT lymphocyte responsesPositive healthy donorsInterferon-gamma productionT lymphocyte populationsPeripheral blood leukocytesCytokine profileELISPOT assayCytokine expressionTrefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. British Journal Of Cancer 2008, 99: 768-773. PMID: 18682706, PMCID: PMC2528153, DOI: 10.1038/sj.bjc.6604546.Peer-Reviewed Original ResearchConceptsTrefoil factor 3Novel serum markerG3 EECSerum markersEndometrial carcinomaHigh-grade endometrial carcinomasEndometrial hyperplasia patientsEndometrioid endometrial carcinomaEndometrial hyperplasiaSerum levelsHyperplasia patientsHealthy patientsSerum concentrationsQuantitative real-time PCRHealthy controlsReal-time PCREndometrium biopsyTFF3 expressionPatientsTFF3 proteinEarly detectionGene expression profilingProtein levelsQRT-PCRExpression levelsTrastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International Journal Of Gynecology & Obstetrics 2008, 102: 128-131. PMID: 18555254, DOI: 10.1016/j.ijgo.2008.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCA-125 AntigenDisease ProgressionEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalReceptor, ErbB-2TrastuzumabConceptsMetastatic endometrial carcinomaHER2/neuEndometrial carcinomaSingle agentCA-125 evaluationHER2/neu receptorRecurrent metastatic diseaseRecurrent endometrial carcinomaEffect of trastuzumabSerial CT scansViable therapeutic optionC-erbB2 gene amplificationSalvage chemotherapyClinical responseMetastatic diseaseTrastuzumab treatmentTherapeutic optionsStudy criteriaDisease progressionCT scanPatientsTrastuzumabNeu receptorChemotherapyRadiation treatment
2001
The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences
O’Brien T, Beard J, Underwood L, Dennis R, Santin A, York L. The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences. Tumor Biology 2001, 22: 348-366. PMID: 11786729, DOI: 10.1159/000050638.Peer-Reviewed Original ResearchConceptsThreonine-rich sequenceAmino acid repeat unitsShort cytoplasmic tailAmino-terminal domainRepeat unitsTransmembrane domainCytoplasmic tailRepeat domainTerminal domainO-glycosylationBiological functionsRepeat sequencesCytoplasmic phosphorylationEpitope binding sitesExtracellular domainExtracellular structuresCysteine loopProtein coreTransmembrane glycoproteinLarge transmembrane glycoproteinProteolytic cleavageGenesBinding sitesPhysiologic roleSequence